DexCom, a pioneer in real-time continuous glucose monitoring (CGM), has announced that Stelo, the first over-the-counter glucose biosensor in the United States, is now available for purchase without a prescription. For the 125 million Americans with Type 2 diabetes who are not using insulin and those with prediabetes, Stelo offers personalized glucose insights that are delivered directly to a smartphone. Users are able to comprehend the impact of food, exercise, and sleep on their glucose levels through the use of this convenient alternative to uncomfortable fingersticks.
Particularly for individuals who lack insurance coverage for prescription glucose biosensors, Stelo broadens access to critical health technology. Stelo.com offers it for purchase, and it is also eligible for FSA and HSA. The biosensor provides substantial health benefits, as research has demonstrated that participants with Type 2 diabetes who utilize CGM technology experience enhanced A1c levels and an overall higher quality of life.
Stelo is now a part of Dexcom's extensive portfolio of glucose monitoring systems, which includes the Dexcom G6 and G7, which are specifically designed for individuals with diabetes who are at risk of hypoglycemia or use insulin. Dexcom, headquartered in San Diego, remains at the forefront of diabetes care technology, providing innovative, user-friendly solutions that enable millions of users to manage their health.
